R&D channel feed

Af­ter re­cruit­ing an As­traZeneca vet as CEO to head a new team and rais­ing $139M cash, lit­tle Ole­ma ap­pears to be ready to launch … some­thing

5 years ago
Financing

Roche shells out $200M for rights to Vac­ci­body's neoanti­gen can­cer vac­cine

5 years ago
Deals

Sol­id gets an­oth­er shot in DMD gene ther­a­py race as FDA lifts hold. But is it too late to catch Pfiz­er, Sarep­ta?

5 years ago
Cell/Gene Tx
FDA+

Gen­fit prunes near­ly half its work­force af­ter NASH ex­it — but CEO promis­es a fu­ture in PBC, di­ag­nos­tics

5 years ago

RNAi trail­blaz­er Al­ny­lam teas­es more pos­i­tive da­ta for a po­ten­tial third com­mer­cial drug

5 years ago

BAR­DA boosts the fight against an­tibi­ot­ic-re­sis­tant in­fec­tions with $144M awards

5 years ago

A new law could open the door to Cal­i­for­ni­a's own drug pipeline. The state has its sights set on in­sulin first

5 years ago
Pharma

Dis­trict Court throws out Cat­a­lyst law­suit al­leg­ing im­prop­er ap­proval stan­dards for ri­val LEMS drug

5 years ago
FDA+

Re­gen­eron of­fers a pos­i­tive look at the first cut of its Covid-19 an­ti­body cock­tail — but just how well does it pro­tect a vul­ner­a­ble group?

5 years ago
Coronavirus

Eye­ing their first ap­proval, Bridge­Bio sends their first drug to the FDA and lands a speedy re­view

5 years ago
FDA+

My­ovant shows dis­ap­point­ing prostate can­cer da­ta on the way to the FDA, stock sinks

5 years ago

Two years af­ter Alex Den­ner ac­tivist at­tack, Iron­wood plots mass lay­offs as last clin­i­cal pro­gram goes up in smoke

5 years ago

Armed with a PhI can­cer drug from Bay­er, an Ac­er­ta founder breaks cov­er and writes him­self a $60M blank check deal

5 years ago
Financing
Deals

Rac­ing ahead of Mer­ck and In­novent, Jun­shi de­clares PhI­II suc­cess on can­cer that won them 'break­through' sta­tus

5 years ago

Hooked by the sci­ence, Arie Bellde­grun joins a group of in­flu­en­tials who be­lieve Dew­point may have the key to the next big thing in biotech

5 years ago
Financing

One year af­ter Fetro­ja ap­proval, Sh­iono­gi ex­pands la­bel to in­clude dif­fi­cult-to-treat pneu­mo­nia

5 years ago
FDA+

In­ven­tis­Bio reels in $147M to push gout and breast can­cer drugs along

5 years ago
Financing

At two-year fol­low-up, Evrys­di con­tin­ues to show nu­mer­i­cal im­prove­ments in da­ta, Roche says

5 years ago

Pal­la­dio bags $20 mil­lion Se­ries B to top­ple a prob­lem­at­ic kid­ney dis­ease drug

5 years ago
Financing

Fol­low­ing a hefty Se­ries B, Sil­ver­back Ther­a­peu­tics quick­ly pulls in $85M for 'an im­por­tant growth phase'

5 years ago
Financing

Monte Rosa rakes in $96M Se­ries B as it pre­pares 'mol­e­c­u­lar glue' plat­form for IND-en­abling stud­ies

5 years ago
Financing

PhII Alzheimer's fail­ure deals new blow to Roche, AC Im­mune — but the tau hy­poth­e­sis is far from dead

5 years ago

Blue­print plots re­turn to FDA with new Ay­vak­it da­ta in rare con­di­tion — and the an­a­lysts cheer

5 years ago

Flag­ship's merged biotech Reper­toire nets ex-Pfiz­er CSO An­tho­ny Coyle as R&D chief

5 years ago
People
First page Previous page 187188189190191192193 Next page Last page
A service from the Financial Times